The Vyleesi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Vyleesi (bremelanotide) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Vyleesi (bremelanotide) Mechanism of Action: Melanocortin receptor agonist, which activates melanocortin receptors […]
The Aimovig Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Aimovig (erenumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Aimovig (erenumab) Mechanism of Action: CGRP (calcitonin gene-related peptide) receptor antagonist, which […]
The Zepatier Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Zepatier (elbasvir/grazoprevir) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zepatier (elbasvir/grazoprevir) Mechanism of Action: NS5A inhibitor (elbasvir) and NS3/4A protease […]
The Addyi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Addyi (flibanserin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Addyi (flibanserin) Mechanism of Action: Serotonin 1A receptor agonist and […]